Nisamox Palatable Tablets 500mg

Main information

  • Trade name:
  • Nisamox Palatable Tablets 500mg
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Nisamox Palatable Tablets 500mg
    Spain
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • ampicillin and enzyme inhibitor
  • Therapeutic area:
  • Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0246/001
  • Authorization date:
  • 20-10-2011
  • EU code:
  • UK/V/0246/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

SUMMARYOFPRODUCTCHARACTERISTICS

1. NameoftheVeterinaryMedicinalProduct

NisamoxPalatableTablets500 mgforDogs

NisamoxTablets400mg/100mgforDogs(France)

2. QualitativeandQuantitativeComposition

Eachtabletcontains:

ActiveIngredients:

Amoxicillin(asamoxicillintrihydrate) 400 mg

Clavulanicacid(aspotassiumclavulanate) 100 mg

ColouringAgent:

CarmoisineLake(E122) 2.45 mg

Forafulllistofexcipients,seeSection6.1.

3. PharmaceuticalForm

Tablet.Pinkdivisiblecirculartabletwithscorelineononefaceandfigure

500 embossedonopposingface.Thetabletcanbedividedintoequalhalves.

4. ClinicalParticulars

4.1 TargetSpecies:

Dogs

4.2 IndicationsforUse, Specifying theTargetSpecies:

Treatmentofthefollowinginfectionscausedbybeta-lactamaseproducing

strainsofbacteriasensitiveto amoxicillinincombinationwithclavulanicacid:

-Skininfections(includingsuperficialanddeeppyodermas)causedby

susceptibleStaphylococci.

-Urinary tract infections causedbysusceptibleStaphylococcior

Escherichiacoli.

-RespiratoryinfectionscausedbysusceptibleStaphylococci.

-EnteritiscausedbysusceptibleEscherichiacoli.

Itisrecommendedtocarryoutsuitabletestsforsensitivitywheninitiatingthe

treatment.Thetreatmentshouldonlyproceedifsensitivityisproventothe

combination.

4.3 Contraindications:

Donotuseinanimalswithknowncasesofhypersensitivitytopenicillinsor

othersubstancesofthebeta-lactamgroup.

Donotuseinrabbits,guineapigs,hamstersorgerbils.

Donotuseinanimalswithseriousdysfunctionofkidneysaccompaniedby

anuriaoroliguria.

Donotusewhereresistanceto thecombinationisknownto occur

4.4 SpecialWarningsforEachTargetSpecies

None.

4.5 SpecialPrecautionsforUse:

(i)Specialprecautionsforuseinanimals:

Inappropriateuseoftheproductmayincreasetheprevalenceofbacteria

resistanttoamoxicillin/clavulanicacid.

Inanimalswithhepaticandrenalfailure,thedosingregimenshouldbe

carefullyevaluated.

Useoftheproductshouldbebasedonsusceptibilitytestingandtakeinto

accountofficialandlocalantimicrobialpolicies.Narrowspectrum

antibacterialtherapyshouldbeusedforfirstlinetreatmentwhere

susceptibilitytestingsuggestslikelyefficacyofthisapproach.

Cautionisadvisedintheuseinsmallherbivoresotherthanthosein4.3.

Donotadministerto horsesandruminatinganimals.

(ii)Specialprecautionstobetakenbythepersonadministeringthe

veterinarymedicinalproductto animals:

Penicillinsandcephalosporinsmaycausehypersensitivity(allergy)following

injection,inhalation,ingestionorskincontact.Hypersensitivitytopenicillins

mayleadtocrossreactionstocephalosporinsandviceversa.Allergic

reactionsto thesesubstancesmayoccasionallybeserious.

Handlethisproductwithgreatcaretoavoidexposure,takingallrecommended

precautions.

Ifyoudevelopsymptomsfollowingexposuresuchasaskinrash,youshould

seekmedicaladviceandshowthedoctorthiswarning.Swellingoftheface,

lipsoreyesordifficultywithbreathingaremoreserioussymptomsand

requireurgentmedicalattention.

Washhandsafteruse.

4.6 AdverseReactions(frequencyand seriousness):

Hypersensitivityunrelatedtodosecanoccurwiththeseagents.

Gastrointestinal symptoms (diarrhoea, vomiting) may occur after

administrationoftheproduct.

Allergicreactions(e.g.skinreactions,anaphylaxia)mayoccasionallyoccur.

Incaseofoccurrenceofallergicreaction,thetreatmentshouldbewithdrawn.

4.7 UseDuring Pregnancy, LactationorLay:

Studiesinlaboratoryanimalshavenotproducedanyevidenceofteratogenic

effects.Useonlyaccordingtotherisk/benefitassessmentbytheresponsible

veterinarian.

4.8 InteractionswithOtherMedicinalProductsandOtherFormsof

Interaction:

Phenicols,macrolides,sulfonamidesandtetracyclinesmayinhibitthe

antibacterialeffectofpenicillinbecauseoftherapidonsetofbacteriostatic

action.

Thepotentialforallergiccross-reactivitywithotherpenicillinsshouldbe

considered.

Penicillinsmayincreasetheeffectsofaminoglycoside.

4.9 Amountsto beAdministered and Administration:

Administrationisviatheoralroute.Thedosagerateis12.5mgcombined

actives/kgbodyweighttwicedaily.Thetabletsmaybecrushedandaddedtoa

littlefood.

Thefollowingtableisintendedasaguidetodispensingtheproductatthe

standarddoserateof12.5 mg/kgtwicedaily.

Bodyweight(kg) Numberoftablets(500 mg)perdosetwicedaily

20 kg ½

40 kg 1

60 kg 1½

80 kg 2

Durationoftherapy:

Routinecasesinvolvingallindications:Themajorityofcasesrespondto

between5 and7 daystherapy.

Chronicorrefractorycases:Inthesecaseswherethereisconsiderabletissue

damage,alongercourseoftherapymayberequiredinthatitallowssufficient

timefordamagedtissuetorepair.

4.10 Overdose(Symptoms,EmergencyProcedures,Antidotes)ifnecessary:

Noadverseeffectshavebeenreportedafterthedailyadministrationof3times

therecommendeddosefor8days,andafterthedailyadministrationofthe

recommendeddosefor21 days.

4.11 WithdrawalPeriod(s):

Notapplicable

5. PharmacologicalProperties

Pharmacotherapeuticgroup:Anti-infectiveforsystemicuse:amoxicillin

andenzymeinhibitor.

ATCvetcode:QJ01CR02

5.1 Pharmacodynamicproperties:

Amoxicillinisabeta-lactamantibioticanditsstructurecontainsthebeta-

lactamringandthiazolidineringcommontoallpenicillins.Amoxicillin

showsexcellentactivityagainstsusceptibleGram-positivebacteriaandGram-

negativebacteria.

Beta-lactamantibioticspreventthebacterialcellwallfromformingby

interferingwiththefinalstageofpeptidoglycansynthesis.Theyinhibitthe

activityoftranspeptidaseenzymes,whichcatalysecross-linkageofthe

glycopeptidepolymerunitsthatformthecellwall.Theyexertabactericidal

actionbutcauselysisofgrowingcellsonly.

Clavulanicacidisoneofthenaturallyoccurringmetabolitesofthe

streptomyceteStreptomycesclavuligerus.Ithasastructuralsimilaritytothe

penicillinnucleus,includingpossessionofabeta-lactamring.Clavulanicacid

isabeta-lactamaseinhibitoractinginitiallycompetitivelybutultimately

irreversibly.Clavulanicacidwillpenetratethebacterialcellwallbindingto

bothextracellularandintracellularbeta-lactamases.

Amoxicillinissusceptibletobreakdownby 

-lactamaseandtherefore

combinationwithaneffectiveß-lactamaseinhibitor(clavulanicacid)extends

therangeofbacteriaagainstwhichitisactivetoinclude 

-lactamase

producingspecies.

Invitropotentiatedamoxicillinisactiveagainstawiderangeofclinically

importantaerobicandanaerobicbacteriaincluding:

Gram-positive:Staphylococci(includingβ-lactamaseproducingstrains).

Gram-negative:Escherichiacoli(includingmostβ-lactamaseproducing

strains).

Resistanceisshownamongmethicillin-resistantStaphylococcusaureus.

DogsdiagnosedwithPseudomonasinfectionsshouldnotbetreatedwiththis

antibioticcombination.AtrendinresistanceofE. coliisreported.

5.2 PharmacokineticParticulars:

Amoxicilliniswell-absorbedfollowingoraladministration.Indogsthe

systemicbioavailabilityis60-70%.Amoxicillin(pKa2.8)hasarelatively

smallapparentdistributionvolume,alowplasmaproteinbinding(34%in

dogs)andashortterminalhalf-lifeduetoactivetubularexcretionviathe

kidneys.Followingabsorptionthehighestconcentrationsarefoundinthe

kidneys(urine)andthebileandtheninliver,lungs,heartandspleen.The

distributionofamoxicillintothecerebrospinalfluidislowunlessthe

meningesareinflamed.

Clavulanicacid(pKa2.7)isalsowell-absorbedfollowingoraladministration.

Thepenetrationtothecerebrospinalfluidispoor.Theplasmaproteinbinding

isapproximately25%andtheeliminationhalf-lifeisshort.Clavulanicacidis

heavilyeliminatedbyrenalexcretion(unchangedinurine).

Afteroraladministrationofthe50mgpresentationattherecommendeddose

of12.5mgcombinedactives/kgtodogs,thefollowingparameterswere

observed:Cmaxof6.30+/-0.45µg/ml,Tmaxof1.98+/-0.135handAUCof

23.38+/-1.39µg/ml.hforamoxicillinandCmaxof0.87+/-0.1µg/ml,Tmax

of1.57 +/-0.177hrsandAUCof1.56 +/-0.24mg/ml.hforclavulanicacid.

6. PharmaceuticalParticulars

6.1 ListofExcipient(s)

LakeCarmosine(E122)

SodiumStarchGlycolate(typeA)

Copovidone

MagnesiumStearate

Cellulose,microcrystalline

SiliconDioxide

CalciumCarbonate

MagnesiumCarbonate,heavy

RoastBeefFlavour

6.2 Incompatibilities

Notapplicable.

6.3 Shelf-Life:

Shelf-lifeofveterinaryproductaspackagedforsale:2 years.

Shelf-lifeafterfirstopeningtheimmediatepackaging:24hours.

Anydividedtabletportionremainingafter24 hoursshouldbediscarded.

6.4 SpecialPrecautionsforStorage:

Donotstoreabove25

C.Storeinadryplace.Dividedtabletsshouldbe

storedintheblisterpack.

6.5 Natureand CompositionofImmediatePackaging:

Theproductispresentedasfollows:

Aluminium/aluminiumblisterstrips,eachcontaining5tablets.Cartonsof10,

20, 25 and100 tablets.Notallpack sizesmaybemarketed.

6.6 SpecialPrecautionsfortheDisposalofUnusedVeterinaryMedicinal

ProductsorWasteMaterialsDerivedfromtheUseofSuchProductsif

appropriate:

Anyunusedproductorwastematerialshouldbedisposedofinaccordance

withnationalrequirements.

7. MarketingAuthorisationHolder

Norbrook LaboratoriesLimited

StationWorks

CamloughRoad

Newry

Co. Down,BT356JP

NorthernIreland

8. MarketingAuthorisationNumber

Vm02000/4260

9. DateofFirstAuthorisation

June2006

10. DateofRevisionofText

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

NotApplicable

22-11-2018

Foreign Product Alert: Black Ant King tablets, Gold Viagra 9800mg capsules, LIPRO Dietary capsules, Stree Overlord Strong tablets (pills), Vegetal Vigra capsules, ViaGro 500mg Male Enhancement capsules

Foreign Product Alert: Black Ant King tablets, Gold Viagra 9800mg capsules, LIPRO Dietary capsules, Stree Overlord Strong tablets (pills), Vegetal Vigra capsules, ViaGro 500mg Male Enhancement capsules

These foreign health products have been found by regulators in other countries to contain undeclared drug ingredients.

Health Canada

There are no news related to this product.